Artivion (NYSE:AORT) SVP Jean Holloway Sells 8,962 Shares

Artivion, Inc. (NYSE:AORT) SVP Jean Holloway sold 8,962 shares of the business’s stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $38.00, for a total value of $340,556.00. Following the transaction, the senior vice president owned 185,095 shares of the company’s stock, valued at approximately $7,033,610. This represents a 4.62% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Artivion Stock Performance

Artivion stock traded down $0.64 during mid-day trading on Thursday, hitting $37.86. 18,366 shares of the company’s stock traded hands, compared to its average volume of 409,237. The company has a quick ratio of 2.62, a current ratio of 3.53 and a debt-to-equity ratio of 0.49. Artivion, Inc. has a one year low of $21.97 and a one year high of $48.25. The firm has a 50 day moving average price of $41.42 and a 200 day moving average price of $42.92. The company has a market cap of $1.81 billion, a PE ratio of 189.31 and a beta of 1.60.

Artivion (NYSE:AORT) last released its quarterly earnings results on Thursday, February 12th. The company reported $0.17 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.14 by $0.03. Artivion had a return on equity of 7.43% and a net margin of 2.21%.The company had revenue of $118.30 million during the quarter, compared to analysts’ expectations of $116.42 million. The company’s revenue was up 19.2% on a year-over-year basis. On average, equities analysts forecast that Artivion, Inc. will post 0.37 EPS for the current year.

Institutional Investors Weigh In On Artivion

Large investors have recently modified their holdings of the stock. Aster Capital Management DIFC Ltd raised its position in shares of Artivion by 402.3% during the third quarter. Aster Capital Management DIFC Ltd now owns 648 shares of the company’s stock worth $27,000 after purchasing an additional 519 shares during the period. Caitong International Asset Management Co. Ltd acquired a new position in shares of Artivion in the 3rd quarter valued at $27,000. Larson Financial Group LLC increased its stake in Artivion by 148.5% in the 4th quarter. Larson Financial Group LLC now owns 942 shares of the company’s stock worth $43,000 after purchasing an additional 563 shares in the last quarter. USA Financial Formulas raised its holdings in Artivion by 163.5% during the 4th quarter. USA Financial Formulas now owns 1,133 shares of the company’s stock worth $52,000 after buying an additional 703 shares during the period. Finally, Smartleaf Asset Management LLC lifted its stake in Artivion by 47.7% during the second quarter. Smartleaf Asset Management LLC now owns 1,667 shares of the company’s stock valued at $52,000 after buying an additional 538 shares in the last quarter. 86.37% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on AORT. Weiss Ratings raised shares of Artivion from a “sell (d)” rating to a “hold (c-)” rating in a research note on Friday, February 20th. Canaccord Genuity Group cut their target price on Artivion from $51.00 to $48.00 and set a “buy” rating for the company in a research report on Friday, February 13th. Wall Street Zen lowered Artivion from a “buy” rating to a “hold” rating in a research note on Saturday, February 14th. Citizens Jmp boosted their price objective on Artivion from $47.00 to $53.00 and gave the stock a “market outperform” rating in a research note on Friday, November 7th. Finally, Oppenheimer reaffirmed an “outperform” rating and set a $50.00 target price on shares of Artivion in a research note on Friday, November 7th. Six analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $48.97.

Key Artivion News

Here are the key news stories impacting Artivion this week:

• Positive Sentiment: Management will present at the Oppenheimer 36th Annual Healthcare MedTech & Services Conference (virtual fireside chat) — a near‑term opportunity for management to update guidance, commercialization progress or product milestones that could re‑ignite buy‑side interest. Artivion to Participate in Oppenheimer Conference
• Positive Sentiment: Recent quarter (Feb. 12) beat EPS and revenue estimates and showed ~19% YoY revenue growth — supports the growth story and underpins analyst conviction. MarketBeat – Artivion Earnings Summary
• Positive Sentiment: Large institutional buyers have been increasing exposure (notably Invesco’s sizable Q4 add and other funds raising positions), which can provide steadier bid support and signal professional investor confidence. MarketBeat – Institutional Activity
• Neutral Sentiment: Analyst coverage remains constructive overall (consensus “Moderate Buy”, average target ≈ $49) — helpful for demand but much of this view appears priced in. MarketBeat – Analyst Ratings
• Neutral Sentiment: Media pieces highlight portfolio expansion and relative EPS performance on the NYSE Composite; these bolster narrative but are not immediate catalysts on their own. Portfolio Expansion Article
• Negative Sentiment: A cluster of senior insider sales from March 2–4 (including CEO James Mackin, EVP Lance Berry, multiple SVPs and the CAO) — markets often treat concentrated insider selling as a near‑term negative signal even though insiders retain large stakes; monitor whether additional sales or explanations (planned sales, tax/liquidity needs) surface. Insider Trades Alert

Artivion Company Profile

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.